证券代码：603896 证券简称：寿仙谷 公告编号：2025-077 债券代码：113660 债券简称：寿22转债 浙江寿仙谷医药股份有限公司 关于举办2025年第二次投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药股份有限公司（以下简 称"公司"或"寿仙谷"）情况，公司拟举办2025年第二次投资者接待日活动，现将有关事项公告如下： 1、接待时间：2025年12月23日8:50-17:00 2、接待地点：公司基地一寿仙谷有机国药养生园；公司总部一浙江省武义县黄龙三路12号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李振宇、董事兼副总经理林荣 志、董事兼副总经理徐靖、董事黄俊华、副总经理兼董事会秘书刘国芳、财务负责人祝彪、副总经理王 汉波、投资者服务部总监曹秀娟（如遇特殊情况，参会人员会有所调整） 4、活动日程： ■ 注：①投资者可根据自己的行程选择合适的集合地点，公司将统一安排车辆前往基地参观；自驾的投资 者可以将 ...

证券日报网讯 12月9日，寿仙谷在互动平台回答投资者提问时表示，公司已开始布局国际市场，特别是 在中医药文化认同度较高的东南亚地区。 （文章来源：证券日报） ...

浙江寿仙谷医药股份有限公司 关于举办 2025 年第二次投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-077 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 为更好与投资者沟通交流，便于广大投资者全面深入地了解浙江寿仙谷医药 股份有限公司（以下简称"公司"或"寿仙谷"）情况，公司拟举办 2025 年第二 次投资者接待日活动，现将有关事项公告如下： 1、接待时间：2025 年 12 月 23 日 8:50-17:00 2、接待地点：公司基地—寿仙谷有机国药养生园；公司总部—浙江省武义 县黄龙三路 12 号。 3、公司主要参与人员：董事长李明焱、副董事长李振皓、董事兼总经理李 振宇、董事兼副总经理林荣志、董事兼副总经理徐靖、董事黄俊华、副总经理兼 董事会秘书刘国芳、财务负责人祝彪、副总经理王汉波、投资者服务部总监曹秀 娟（如遇特殊情况，参会人员会有所调 ...

公司代码：603896 公司简称：寿仙谷 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. （浙江省武义县壶山街道商城路 10 号） 2025 年第二次临时股东会 会议资料 $$=0\pm\pi\pm\pi\pm\pi\pm\pi\pm\pi\pm\pi$$ 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议资料 目 录 | 2025 | 年第二次临时股东会会议议程 2 | | --- | --- | | 2025 | 年第二次临时股东会会议须知 4 | | | 议案一：关于变更公司注册资本、取消监事会暨修订《公司章程》的议案 6 | | | 议案二：关于修订部分公司治理制度的议案 14 | 1 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议资料 浙江寿仙谷医药股份有限公司 2025 年第二次临时股东会会议议程 一、会议召集人：浙江寿仙谷医药股份有限公司董事会 二、会议召开的日期、时间： 现场会议时间：2025 年 12 月 23 日 14:00 网络投票起止时间：自 ...

Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on December 23, 2025 [2][5] - The meeting will utilize a combination of on-site and online voting methods, with specific time slots for voting [3][6] - The company aims to enhance participation from small and medium investors by providing reminder services for the meeting [3][4] Group 2 - The company plans to provide a guarantee of 600 million RMB for its wholly-owned subsidiaries within a comprehensive credit limit for 2026 [20][21] - As of the announcement date, the actual guarantee balance provided to subsidiaries is 190 million RMB [21][26] - The company intends to apply for a total credit limit of up to 800 million RMB from various financial institutions [21][25] Group 3 - The company has decided to postpone the expected usable status date for two fundraising investment projects from November 30, 2025, to June 30, 2026 [29][36] - The postponement does not alter the total investment amount or construction scale of the projects [29][37] - The company emphasizes that the delay is a cautious decision based on market conditions and will not significantly impact its normal operations [37][39] Group 4 - The company has revised its remuneration management system for directors and senior management to align with current regulations and improve internal governance [42] - The revised system was approved during the sixth meeting of the fifth board of directors [42][41] Group 5 - The company plans to use up to 250 million RMB of temporarily idle fundraising and up to 1 billion RMB of idle self-owned funds for cash management in 2026 [55][56] - The investment will focus on low-risk financial products such as structured deposits and large certificates of deposit [58][64] - The decision to manage idle funds aims to enhance capital efficiency without affecting ongoing projects or normal operations [70][71]

证券日报网讯11月28日晚间，寿仙谷（603896）发布公告称，公司对外担保不存在逾期情形。 ...

Group 1 - The core point of the article is that Shouxiangu (SH 603896) held its sixth meeting of the fifth board of directors on November 28, 2025, to discuss the revision of the "Compensation Management System for Directors and Senior Management" [1] - For the first half of 2025, Shouxiangu's revenue composition was as follows: manufacturing accounted for 95.69%, other businesses accounted for 2.67%, and additional business activities accounted for 1.63% [1] - As of the time of reporting, Shouxiangu's market capitalization was 4 billion yuan [1]

国信证券股份有限公司 关于浙江寿仙谷医药股份有限公司 2026 年度使用部分 暂时闲置募集资金及自有资金进行现金管理的核查意见 国信证券股份有限公司（以下简称"国信证券"）作为浙江寿仙谷医药股份 有限公司（以下简称"寿仙谷"或"公司"）公开发行可转换公司债券并上市的 保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规 则》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等相关法律法规和规范性文件的要求， 经审慎核查，就寿仙谷拟使用部分暂时闲置募集资金及自有资金进行现金管理的 事项，发表专项核查意见如下： 一、募集资金基本情况 （一）2020 年公开发行可转换公司债券募集资金 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准浙江寿 仙谷医药股份有限公司公开发行可转换公司债券的批复》（证监许可[2020] 658 号） 核准，公司已公开发行总额为人民币 36,000 万元可转换公司债券，每张面值 100 元人民币，共 3,600,000 张，期限为 6 年。扣除公司为本次可转换公司债券所支 付的发行费用后，实际 ...